The author of today’s article made a mistake when they previously went against their rules for trading a premium-priced biotech and jumped on a small-cap pharmaceutical stock focused on women’s health issues. Now, however, they see the stock as presenting a great contrarian opportunity. Here’s some of what they have to say: “The company had a rough time with the COVID-19 pandemic, but I believe it is primed to make a strong resurgence as the country opens up and the women’s health industry returns to normal operations.” For more, CLICK HERE.
This Women’s Healthcare Stock Has Gone From Mistake To Contrarian Opportunity
Tags:Biotech StocksContrarian OpportunityCOVID-19 PandemicHealthcare InvestmentsInvestingInvestorPharma StocksPremium-Priced BiotechSmall-Cap Pharmaceutical Stocksstock marketWomen's Health IndustryWomen's Health Issues